Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
B 22.26 0.09% 0.02
ALKS closed up 0.09 percent on Friday, May 14, 2021, on 1.23 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ALKS trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
Cup with Handle Other 0.00%
NR7 Range Contraction 0.00%
Bearish Engulfing Bearish 0.09%
MACD Bearish Signal Line Cross Bearish 0.09%
Cup with Handle Other 0.09%
Shooting Star Candlestick Bearish -0.80%
Cup with Handle Other -0.80%
20 DMA Support Bullish -0.36%
Bullish Engulfing Bullish -0.36%
Older End-of-Day Signals for ALKS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 2 days ago
10 DMA Support 2 days ago
Down 1% 2 days ago
Fell Below 10 DMA 2 days ago
Fell Below Previous Day's Low 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alkermes plc Description

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Surgery Alcohol Diabetes Chemotherapy Hypertension Opioid Schizophrenia Lipid Spas Multiple Sclerosis Mild Organic Chemistry Cholesterol Depressive Disorder Morphinans Neurochemistry Nausea Attention Deficit Hyperactivity Disorder Angina Constipation Treatment Of Schizophrenia Cachexia I Diabetes Janssen Pharmaceutica Obsessive Compulsive Disorder Ii Diabetes Cocaine Opioid Antagonists Opioid Receptors Spasticity Transplant Rejection Treatment Of Multiple Sclerosis Atypical Antipsychotics Luvox Cr Opioid Induced Constipation Pharmaceutical Wholesalers Renal Transplant Zanaflex

Is ALKS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.92
52 Week Low 15.35
Average Volume 1,317,130
200-Day Moving Average 19.18
50-Day Moving Average 20.33
20-Day Moving Average 21.74
10-Day Moving Average 22.14
Average True Range 0.66
ADX 23.66
+DI 23.33
-DI 20.29
Chandelier Exit (Long, 3 ATRs ) 21.01
Chandelier Exit (Short, 3 ATRs ) 21.29
Upper Bollinger Band 23.23
Lower Bollinger Band 20.26
Percent B (%b) 0.67
BandWidth 13.65
MACD Line 0.59
MACD Signal Line 0.62
MACD Histogram -0.0211
Fundamentals Value
Market Cap 3.54 Billion
Num Shares 159 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -19.03
Price-to-Sales 2.50
Price-to-Book 2.72
PEG Ratio -1057.29
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.84
Resistance 3 (R3) 22.79 22.55 22.74
Resistance 2 (R2) 22.55 22.41 22.58 22.71
Resistance 1 (R1) 22.41 22.32 22.48 22.45 22.68
Pivot Point 22.17 22.17 22.21 22.19 22.17
Support 1 (S1) 22.02 22.02 22.10 22.07 21.84
Support 2 (S2) 21.78 21.93 21.81 21.81
Support 3 (S3) 21.64 21.78 21.78
Support 4 (S4) 21.68